Content Pillar: Healthcare Market Access
To prove value, your startup must move beyond theoretical innovation and align with clinician workflows. Success requires a “Chief No Officer” on your advisory board to challenge the status quo, ensuring your product solves real-world adoption friction rather than just functioning as a technical achievement.
Table of Contents
- Why Do Clinically Proven Healthtech Solutions Struggle With Adoption?
- What Does It Mean to Have a “Chief No Officer” on Your Board?
- How Do You Balance Technological Sophistication With Market Readiness?
- Why Should You Seek Strategic Partners Instead of Just Investors?
- FAQ: Scaling Healthtech Startups With Clinical Integrity
Healthtech founders often build products in a vacuum, ignoring the harsh reality of fragmented healthcare systems. If you want to prove value in a healthcare system, you must stop selling technical features and start solving operational friction. In this article, we draw on insights from advisor Mitchell Fong to show you how to move from pilot testing to sustainable growth by aligning your innovation with the needs of the clinicians who use it every day.
Why Do Clinically Proven Healthtech Solutions Struggle With Adoption?
The clinical adoption gap is the graveyard of early-stage healthtech.
You may have a solution that performs exceptionally well in testing, pilot environments, or controlled studies. That does not guarantee adoption in the real world.
Healthcare is a human ecosystem.
Clinicians operate within established workflows. Health systems manage competing priorities. Patients bring varying levels of trust, comfort, and readiness for change.
During our conversation with healthcare executive and value-based care expert Mitchell Fong, he emphasized an important reality: founders must evaluate whether the market is ready for a specific technology, not simply whether the technology works.
When your product requires clinicians to abandon familiar processes, you are not just selling software.
You are asking people to change behavior.
That is often a much harder sale than founders realize.
The companies that gain traction are not always the ones with the most advanced technology. They are the ones that reduce friction. They introduce innovation in ways that feel familiar, practical, and easy to adopt.
Successful healthtech founders understand that adoption is not a technology problem.
It is a trust problem.
What Does It Mean to Have a “Chief No Officer” on Your Board?
One of the most expensive mistakes founders make is surrounding themselves with people who agree with them.
Strong advisors should support your vision.
They should also challenge your assumptions.
As Mitchell explained:
“I think the first thing I’d say is not having the chief no officer, if you will, on your board.”
Every startup needs someone willing to ask difficult questions.
Is the market actually demanding this feature?
Is the pricing model realistic?
Are customers ready for this level of change?
Is the company solving the right problem?
Without those conversations, founders often spend months building products or features that never generate meaningful adoption or revenue.
Your board should not function as a cheerleading squad.
It should function as a strategic decision-making body made up of operators, clinicians, investors, and industry experts who understand the realities of healthcare.
The right advisor will occasionally tell you what you do not want to hear.
That feedback can save years of wasted effort.
How Do You Balance Technological Sophistication With Market Readiness?
Healthcare history is filled with products that were technically impressive but commercially unsuccessful.
The challenge is not always building breakthrough technology.
The challenge is introducing it at the right time.
Mitchell shared an example involving a startup with a highly advanced robotics solution and a compelling value proposition. The technology offered significant long-term potential. Yet the team recognized that leading with robotics would create resistance among users who were not ready for that level of change.
Instead, they made a strategic decision.
They temporarily moved the robotics component into the background and focused on solutions that providers and patients were already comfortable adopting.
That decision accelerated acceptance.
It also created trust.
Many founders assume their biggest competitive advantage must be highlighted immediately.
In healthcare, that is not always true.
Sometimes the smartest move is introducing innovation gradually.
Build trust first.
Demonstrate value.
Create positive outcomes.
Then expand adoption over time.
The goal is not to showcase the most sophisticated technology.
The goal is to create measurable outcomes that people are willing to embrace.
Why Should You Seek Strategic Partners Instead of Just Investors?
Capital is important, but capital alone rarely solves execution challenges.
Many founders spend years searching for investors while overlooking the value of strategic partners who can help navigate healthcare’s complexity.
As Sabrina Runbeck shared during the interview:
“You can have the best product out there. But if the founder are not able, or at least find someone to represent the brand to create a trust to be able to listen and talk, that means you can have an initial excitement… but then you cannot retain these partners.”
The strongest healthcare companies are built through relationships. They are built through trusted introductions, operational guidance, clinical validation, and people who understand how healthcare actually works.
Investors who focus exclusively on financial returns may miss the operational realities that determine whether a company succeeds or fails.
Strategic partners bring something different.
They understand patient workflows, provider adoption, reimbursement models, and population health. Most importantly, they help founders avoid mistakes before those mistakes become expensive.
The market is already signaling what matters most.
According to the American Medical Association, physician adoption of AI tools nearly doubled from 38% in 2023 to 66% in 2024. Yet clinicians continue to cite workflow integration, trust, accuracy, and ease of use as critical factors influencing adoption. The data reinforces what Mitchell Fong highlighted throughout the discussion: healthcare organizations are not simply buying technology. They are investing in solutions that fit naturally into clinical workflows, improve outcomes, and create measurable value for both providers and patients.
FAQ Section
Validation requires moving beyond technical specs to demonstrate clear outcomes. You must align your solution with existing administrative and clinical workflows while proving a measurable reduction in the total cost of care.
They fail because they often ignore the change management effort required. If a solution is technically sound but adds friction to the clinician’s day, it will likely be rejected by the care team regardless of its efficacy.
Start early. You need to build relationships with investors and experts before you reach the $15M–$20M revenue mark. This allows you to secure strategic alignment while your business model is still flexible enough to adjust.
Ready to Build What Truly Lasts?
Stop being a cog in the wheel of institutional medicine. If you are an accredited clinician with 10+ years of experience, ready to invest with intention and advise with influence, apply for the Health Board Advisors fellowship today to reclaim your clinical legacy.
Apply for membership: HealthBoardAdvisors.com/Apply
About Health Board Advisors
Health Board Advisors (HBA) is the only seed-to-scale clinical investment ecosystem in the U.S. By integrating physician capital with elite operator execution, HBA enables expert clinicians to bypass institutional overshadowing and lead the healthcare AI revolution. Connect with our peer group of investors and visionary leaders on LinkedIn.
Learn more: HealthBoardAdvisors.com
